H.C. Wainwright analyst Douglas Tsao reiterates a Buy rating on Argenx (ARGX) with a $617 price target after the company said it is advancing efgartigimod subcutaneous in all three subtypes of myositis based on positive Phase 2 results. The firm says efgartigimod could potentially be the first targeted treatment for myositis. Given cost and ease of use, it expects efgartigimod would be used ahead of cell therapy.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX: